Europe Clinical Trials Market Research Report Forecast to 2030

The increasing number of clinical trials, rising demand for Contract Research Organizations (CROs) to conduct clinical trials, and strong healthcare infrastructure are some factors propelling the Europe clinical trials market. Due to the digital transformation in clinical trials, the Europe clinical trials industry has a lot of opportunities to grow.

Clinical trials are human-participant prospective biomedical or behavioral research studies designed to answer specific questions concerning biomedical or behavioral interventions, including new treatments and recognized interventions that need additional study and comparison.

The Europe clinical trials market is growth is attributing due to the increasing number of clinical trials and strong healthcare infrastructure. Additionally, the digital transformation in clinical trials, growing incidences of diseases, and increasing approval of new active substances by the Europe Medicine Agency (EMA) will provide growth opportunities for the market in the future. However, the shortage of skilled and experienced professionals might hamper the market's growth in the forecast period.

Market Segmentation

Based on Phase, the Europe clinical trials market has been segmented into Phase I, Phase II, Phase III, And Phase IV.

Based on study design, the Europe clinical trials market has been segmented into observational, interventional, and expanded access.

Based on application, the Europe clinical trials market has been segmented into pharmaceutical, medical devices, nutrition, and others.

Based on service type, the Europe clinical trials market has been segmented into protocol designing, site identification, patient recruitment, laboratory services, bioanalytical testing services, clinical trial data management services, and others.

Based on end user, the Europe clinical trials market has been segmented into pharmaceutical & biotechnology companies, medical device companies, academic & research institutes, and nutraceutical companies.

The Europe clinical trials market includes countries such as Germany, France, the UK, Italy, Spain, Austria, and the rest of Europe. The European clinical trials market is driven by several key factors that contribute to its growth and development. The below mentioned factors align with the overall regional trends in the Europe clinical trials market.

Major Players

IQVIA (US), Laboratory Corporation of America Holdings (US), ICON PLC (Ireland), PPD Inc (US), Syneos Health (US CTI Clinical Trial and Consulting (US), Medpace Inc (US), Charles River Laboratories (US), Parexel International (MA) Corporation (US), and Antaea Medical Services Ltd (Greece).

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
- 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
- 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING NUMBER OF CLINICAL TRIALS
- 4.2.2 STRONG HEALTHCARE INFRASTRUCTURE
4.3 RESTRAINTS
- 4.3.1 SHORTAGE OF SKILLED AND EXPERIENCED PROFESSIONALS
4.4 OPPORTUNITY
- 4.4.1 DIGITAL TRANSFORMATION IN CLINICAL TRIALS
- 4.4.2 GROWING INCIDENCES OF DISEASES
- 4.4.3 INCREASING APPROVAL OF NEW ACTIVE SUBSTANCES BY EUROPE MEDICINE AGENCY(EMA)

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 CUSTOMER ACQUISITION (PREPURCHASE QUERY)
- 5.1.2 SERVICE CUSTOMIZATION
- 5.1.3 CUSTOMER PURCHASE SUPPORT
- 5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON EUROPE CLINICAL TRIAL MARKET
- 5.3.1 OVERVIEW
- 5.3.2 IMPACT ON PRICING
- 5.3.3 IMPACT ON KEY PLAYERS
5.4 LIST OF DRUGS AND DEVICES MANUFACTURERS PRESENCE IN EUROPE

6 EUROPE CLINICAL TRIALS MARKET, BY PHASE

6.1 OVERVIEW
6.2 PHASE I
6.3 PHASE II
- 6.3.1 PHASE IIA
- 6.3.2 PHASE IIB ERROR! BOOKMARK NOT DEFINED.
6.4 PHASE III
6.5 PHASE IV

7 EUROPE CLINICAL TRIALS MARKET, BY STUDY DESIGN

7.1 OVERVIEW
7.2 OBSERVATIONAL
7.3 INTERVENTIONAL
7.4 EXPANDED ACCESS

8 EUROPE CLINICAL TRIALS MARKET, BY APPLICATION

8.1 OVERVIEW
8.2 PHARMACEUTICAL
- 8.2.1 NEUROLOGICAL
- 8.2.2 ONCOLOGY
- 8.2.3 CARDIOVASCULAR
- 8.2.4 INFECTIOUS DISEASES
- 8.2.5 OTHERS
8.3 MEDICAL DEVICES
8.4 NUTRITION
8.5 OTHERS

9 EUROPE CLINICAL TRIALS MARKET, BY SERVICE TYPE

9.1 OVERVIEW
9.2 PROTOCOL DESIGNING
9.3 SITE IDENTIFICATION
9.4 PATIENT RECRUITMENT
9.5 LABORATORY SERVICES
9.6 BIOANALYTICAL TESTING SERVICES
9.7 CLINICAL TRIAL DATA MANAGEMENT SERVICES
9.8 OTHERS

10 EUROPE CLINICAL TRIALS MARKET, BY END USER

10.1 OVERVIEW
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3 MEDICAL DEVICE COMPANIES
10.4 ACADEMIC & RESEARCH INSTITUTES
10.5 NUTRACEUTICAL COMPANIES

11 EUROPE CLINICAL TRIALS MARKET, BY COUNTRY

11.1 OVERVIEW
- 11.1.1 GERMANY
- 11.1.2 FRANCE
- 11.1.3 UK
- 11.1.4 ITALY
- 11.1.5 SPAIN
- 11.1.6 AUSTRIA
- 11.1.7 REST OF EUROPE

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW
12.2 COMPETITIVE BENCHMARKING
12.3 MAJOR GROWTH STRATEGY IN THE EUROPE CLINICAL TRIALS MARKET
12.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE EUROPE CLINICAL TRIALS MARKET
12.5 KEY DEVELOPMENT ANALYSIS
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 12.6.1 SERVICE LAUNCH
- 12.6.2 MERGER/ACQUISITION
- 12.6.3 PARTNERSHIP/COLLABOARTION/AGREEMENT/EXPANSION/INVESTMENT
12.7 FINANCIAL MATRIX
- 12.7.1 SALES (USD MILLION), 2022
- 12.7.2 MARGINS FROM SERVICES OFFERED FOR CLINICAL STUDIES IN THE MEDICAL DEVICE AND PHARMACEUTICAL AREA
- 12.7.3 TURNOVER OF CROS WORLDWIDE, EUROPE-WIDE, AND GERMANY AND AUSTRIA
13.1 CHARLES RIVER LABORATORIES
- 13.1.1 COMPANY OVERVIEW
- 13.1.2 FINANCIAL OVERVIEW
- 13.1.3 SERVICES OFFERED
- 13.1.4 KEY DEVELOPMENTS
- 13.1.5 SWOT ANALYSIS
- 13.1.6 KEY STRATEGIES
13.2 PAREXEL INTERNATIONAL (MA) CORPORATION
- 13.2.1 COMPANY OVERVIEW
- 13.2.2 FINANCIAL OVERVIEW
- 13.2.3 SERVICES OFFERED
- 13.2.4 KEY DEVELOPMENTS
- 13.2.5 KEY STRATEGIES
13.3 ICON PLC
- 13.3.1 COMPANY OVERVIEW
- 13.3.2 FINANCIAL OVERVIEW
- 13.3.3 SERVICES OFFERED
- 13.3.4 KEY DEVELOPMENTS
- 13.3.5 SWOT ANALYSIS
- 13.3.6 KEY STRATEGIES
13.4 LABORATORY CORPORATION OF AMERICA HOLDINGS
- 13.4.1 COMPANY OVERVIEW
- 13.4.2 FINANCIAL OVERVIEW
- 13.4.3 SERVICES OFFERED
- 13.4.4 KEY DEVELOPMENTS
- 13.4.5 SWOT ANALYSIS
- 13.4.6 KEY STRATEGIES
13.5 PPD INC
- 13.5.1 COMPANY OVERVIEW
- 13.5.2 FINANCIAL OVERVIEW
- 13.5.3 SERVICES OFFERED
- 13.5.4 KEY DEVELOPMENTS
- 13.5.5 SWOT ANALYSIS
- 13.5.6 KEY STRATEGIES
13.6 SYNEOS HEALTH
- 13.6.1 COMPANY OVERVIEWS
- 13.6.2 FINANCIAL OVERVIEW
- 13.6.3 SERVICES OFFERED
- 13.6.4 KEY DEVELOPMENTS
- 13.6.5 KEY STRATEGIES
13.7 CTI CLINICAL TRIAL & CONSULTING
- 13.7.1 COMPANY OVERVIEW
- 13.7.2 FINANCIAL OVERVIEW
- 13.7.3 SERVICES OFFERED
- 13.7.4 KEY DEVELOPMENTS
- 13.7.5 KEY STRATEGIES
13.8 IQVIA
- 13.8.1 COMPANY OVERVIEW
- 13.8.2 FINANCIAL OVERVIEW
- 13.8.3 SERVICES OFFERED
- 13.8.4 KEY DEVELOPMENTS
- 13.8.5 SWOT ANALYSIS
- 13.8.6 KEY STRATEGIES
13.9 MEDPACE INC
- 13.9.1 COMPANY OVERVIEW
- 13.9.2 FINANCIAL OVERVIEW
- 13.9.3 SERVICES OFFERED
- 13.9.4 KEY DEVELOPMENTS
- 13.9.5 KEY STRATEGIES
13.10 ANTAEA MEDICAL SERVICES LTD.
- 13.10.1 COMPANY OVERVIEW
- 13.10.2 FINANCIAL ANALYSIS
- 13.10.3 SERVICES OFFERED
- 13.10.4 KEY DEVELOPMENTS
- 13.10.5 KEY STRATEGIES

14 APPENDIX

14.1 REFERENCES
14.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 16
TABLE 2 DIABETES ESTIMATES (20-79 YEARS) FOR 2021, 2030, AND 2045 28
TABLE 3 CHILDREN & ADOLESCENTS AND ADULTS WITH OBESITY IN 2020, 2025, 2030, AND 2035 28
TABLE 4 LIST OF MEDICAL DEVICE MANUFACTURERS 35
TABLE 5 LIST OF DRUGS MANUFACTURERS 36
TABLE 6 EUROPE CLINICAL TRIALS MARKET, FOR PHASE, BY COUNTRY, 2019-2030 (USD MILLION) 38
TABLE 7 EUROPE CLINICAL TRIALS MARKET, FOR PHASE I, BY COUNTRY, 2019-2030 (USD MILLION) 39
TABLE 8 EUROPE CLINICAL TRIALS MARKET, FOR PHASE II, BY COUNTRY, 2019-2030 (USD MILLION) 40
TABLE 9 EUROPE CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019-2030 (USD MILLION) 40
TABLE 10 EUROPE CLINICAL TRIALS MARKET, FOR PHASE IIA, BY COUNTRY, 2019-2030 (USD MILLION) 40
TABLE 11 EUROPE CLINICAL TRIALS MARKET, FOR PHASE IIB, BY COUNTRY, 2019-2030 (USD MILLION) 41
TABLE 12 EUROPE CLINICAL TRIALS MARKET, FOR PHASE III, BY COUNTRY, 2019-2030 (USD MILLION) 41
TABLE 13 EUROPE CLINICAL TRIALS MARKET, FOR PHASE III, BY COUNTRY, 2019-2030 (USD MILLION) 42
TABLE 14 EUROPE CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019-2030 (USD MILLION) 44
TABLE 15 EUROPE CLINICAL TRIALS MARKET, FOR OBSERVATIONAL, BY COUNTRY, 2019-2030 (USD MILLION) 45
TABLE 16 EUROPE CLINICAL TRIALS MARKET, FOR INTERVENTIONAL, BY COUNTRY, 2019-2030 (USD MILLION) 46
TABLE 17 EUROPE CLINICAL TRIALS MARKET, FOR EXPANDED ACCESS, BY COUNTRY, 2019-2030 (USD MILLION) 46
TABLE 18 EUROPE CLINICAL TRIALS MARKET, FOR APPLICATION, BY COUNTRY, 2019-2030 (USD MILLION) 48
TABLE 19 EUROPE CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY COUNTRY, 2019-2030 (USD MILLION) 49
TABLE 20 EUROPE CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019-2030 (USD MILLION) 50
TABLE 21 EUROPE CLINICAL TRIALS MARKET, FOR NEUROLOGICAL, BY COUNTRY, 2019-2030 (USD MILLION) 50
TABLE 22 EUROPE CLINICAL TRIALS MARKET, FOR ONCOLOGY, BY COUNTRY, 2019-2030 (USD MILLION) 51
TABLE 23 EUROPE CLINICAL TRIALS MARKET, FOR CARDIOVASCULAR, BY COUNTRY, 2019-2030 (USD MILLION) 51
TABLE 24 EUROPE CLINICAL TRIALS MARKET, FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2030 (USD MILLION) 52
TABLE 25 EUROPE CLINICAL TRIALS MARKET, FOR OTHERS, BY COUNTRY, 2019-2030 (USD MILLION) 52
TABLE 26 EUROPE CLINICAL TRIALS MARKET, FOR MEDICAL DEVICES, BY COUNTRY, 2019-2030 (USD MILLION) 53
TABLE 27 EUROPE CLINICAL TRIALS MARKET, FOR NUTRITION, BY COUNTRY, 2019-2030 (USD MILLION) 53
TABLE 28 EUROPE CLINICAL TRIALS MARKET, FOR OTHERS, BY COUNTRY, 2019-2030 (USD MILLION) 54
TABLE 29 EUROPE CLINICAL TRIALS MARKET, BY SERVICE TYPE 2019-2030 (USD MILLION) 57
TABLE 30 EUROPE CLINICAL TRIALS MARKET, FOR PROTOCOL DESIGNING, BY COUNTRY, 2019-2030 (USD MILLION) 58
TABLE 31 EUROPE CLINICAL TRIALS MARKET, FOR SITE IDENTIFICATION, BY COUNTRY, 2019-2030 (USD MILLION) 58
TABLE 32 EUROPE CLINICAL TRIALS MARKET, FOR PATIENT RECRUITMENT, BY COUNTRY, 2019-2030 (USD MILLION) 59
TABLE 33 EUROPE CLINICAL TRIALS MARKET, FOR LABORATORY SERVICES, BY COUNTRY, 2019-2030 (USD MILLION) 59
TABLE 34 EUROPE CLINICAL TRIALS MARKET, FOR BIOANALYTICAL TESTING SERVICES, BY COUNTRY, 2019-2030 (USD MILLION) 60
TABLE 35 EUROPE CLINICAL TRIALS MARKET, FOR CLINICAL TRIAL DATA MANAGEMENT SERVICES, BY COUNTRY, 2019-2030 (USD MILLION) 60
TABLE 36 EUROPE CLINICAL TRIALS MARKET, FOR OTHERS, BY COUNTRY, 2019-2030 (USD MILLION) 61
TABLE 37 EUROPE CLINICAL TRIALS MARKET, FOR END USER, BY COUNTRY, 2019-2030 (USD MILLION) 63
TABLE 38 EUROPE CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2030 (USD MILLION) 64
TABLE 39 EUROPE CLINICAL TRIALS MARKET, FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019-2030 (USD MILLION) 65
TABLE 40 EUROPE CLINICAL TRIALS MARKET, FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019-2030 (USD MILLION) 65
TABLE 41 EUROPE CLINICAL TRIALS MARKET, FOR NUTRACEUTICAL COMPANIES, BY COUNTRY, 2019-2030 (USD MILLION) 66
TABLE 42 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2030 (USD MILLION) 70
TABLE 43 GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 2019-2030 (USD MILLION) 71
TABLE 44 GERMANY: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019-2030 (USD MILLION) 71
TABLE 45 GERMANY: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019-2030 (USD MILLION) 72
TABLE 46 GERMANY: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2030 (USD MILLION) 72
TABLE 47 GERMANY: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019-2030 (USD MILLION) 72
TABLE 48 GERMANY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2030 (USD MILLION) 73
TABLE 49 GERMANY: CLINICAL TRIALS MARKET BY END USER, 2019-2030 (USD MILLION) 73
TABLE 50 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2019-2030 (USD MILLION) 74
TABLE 51 FRANCE: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019-2030 (USD MILLION) 74
TABLE 52 FRANCE: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019-2030 (USD MILLION) 74
TABLE 53 FRANCE: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2030 (USD MILLION) 75
TABLE 54 FRANCE: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019-2030 (USD MILLION) 75
TABLE 55 FRANCE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2030 (USD MILLION) 75
TABLE 56 FRANCE: CLINICAL TRIALS MARKET BY END USER, 2019-2030 (USD MILLION) 76
TABLE 57 UK: CLINICAL TRIALS MARKET, BY PHASE, 2019-2030 (USD MILLION) 76
TABLE 58 UK: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019-2030 (USD MILLION) 76
TABLE 59 UK: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019-2030 (USD MILLION) 77
TABLE 60 UK: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2030 (USD MILLION) 77
TABLE 61 UK: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019-2030 (USD MILLION) 77
TABLE 62 UK: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2030 (USD MILLION) 78
TABLE 63 UK: CLINICAL TRIALS MARKET BY END USER, 2019-2030 (USD MILLION) 78
TABLE 64 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2019-2030 (USD MILLION) 79
TABLE 65 ITALY: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019-2030 (USD MILLION) 79
TABLE 66 ITALY: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019-2030 (USD MILLION) 79
TABLE 67 ITALY: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2030 (USD MILLION) 80
TABLE 68 ITALY: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019-2030 (USD MILLION) 80
TABLE 69 ITALY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2030 (USD MILLION) 80
TABLE 70 ITALY: CLINICAL TRIALS MARKET BY END USER, 2019-2030 (USD MILLION) 81
TABLE 71 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2019-2030 (USD MILLION) 81
TABLE 72 SPAIN: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019-2030 (USD MILLION) 81
TABLE 73 SPAIN: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019-2030 (USD MILLION) 82
TABLE 74 SPAIN: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2030 (USD MILLION) 82
TABLE 75 SPAIN: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019-2030 (USD MILLION) 82
TABLE 76 SPAIN: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2030 (USD MILLION) 83
TABLE 77 SPAIN: CLINICAL TRIALS MARKET BY END USER, 2019-2030 (USD MILLION) 83
TABLE 78 AUSTRIA: CLINICAL TRIALS MARKET, BY PHASE, 2019-2030 (USD MILLION) 84
TABLE 79 AUSTRIA: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019-2030 (USD MILLION) 84
TABLE 80 AUSTRIA: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019-2030 (USD MILLION) 84
TABLE 81 AUSTRIA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2030 (USD MILLION) 85
TABLE 82 AUSTRIA: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019-2030 (USD MILLION) 85
TABLE 83 AUSTRIA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2030 (USD MILLION) 85
TABLE 84 AUSTRIA: CLINICAL TRIALS MARKET BY END USER, 2019-2030 (USD MILLION) 86
TABLE 85 REST OF EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2019-2030 (USD MILLION) 86
TABLE 86 REST OF EUROPE: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019-2030 (USD MILLION) 86
TABLE 87 REST OF EUROPE: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019-2030 (USD MILLION) 87
TABLE 88 REST OF EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2030 (USD MILLION) 87
TABLE 89 REST OF EUROPE: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019-2030 (USD MILLION) 87
TABLE 90 REST OF EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2030 (USD MILLION) 88
TABLE 91 REST OF EUROPE: CLINICAL TRIALS MARKET BY END USER, 2019-2030 (USD MILLION) 88
TABLE 92 MAJOR PLAYERS IN THE EUROPE CLINICAL TRIALS MARKET 89
TABLE 93 MOST ACTIVE PLAYER IN THE EUROPE CLINICAL TRIALS MARKET 91
TABLE 94 SERVICE LAUNCH 92
TABLE 95 MERGER/ACQUISITION 93
TABLE 96 PARTNERSHIP/COLLABOARTION/AGREEMENT/EXPANSION/INVESTMENT 93
TABLE 97 MARGINS FROM SERVICES OFFERED FOR CLINICAL STUDIES IN THE MEDICAL DEVICE AND PHARMACEUTICAL AREA, 2022-2023 94
TABLE 98 CHARLES RIVER LABORATORIES: SERVICES OFFERED 98
TABLE 99 PAREXEL INTERNATIONAL (MA) CORPORATION: SERVICES OFFERED 100
TABLE 100 ICON PLC: SERVICES OFFERED 103
TABLE 101 ICON PLC: KEY DEVELOPMENTS 104
TABLE 102 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES OFFERED 107
TABLE 103 PPD INC: SERVICES OFFERED 109
TABLE 104 PPD INC: KEY DEVELOPMENTS 110
TABLE 105 SYNEOS HEALTH: SERVICES OFFERED 114
TABLE 106 SYNEOS HEALTH: KEY DEVELOPMENTS 114
TABLE 107 CTI CLINICAL TRIAL & CONSULTING: SERVICES OFFERED 115
TABLE 108 IQVIA: SERVICES OFFERED 119
TABLE 109 MEDPACE INC: SERVICES OFFERED 122
TABLE 110 ANTAEA MEDICAL SERVICES LTD: SERVICES OFFERED 123

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 13
FIGURE 2 EUROPE CLINICAL TRIALS MARKET STRUCTURE 15
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 21
FIGURE 4 MARKET DYNAMICS: EUROPE CLINICAL TRIALS MARKET 24
FIGURE 5 DRIVER IMPACT ANALYSIS 26
FIGURE 6 RESTRAINT IMPACT ANALYSIS 27
FIGURE 7 NUMBER OF NEW ACTIVE SUBSTANCES FOR DISEASES APPROVED BY EMA IN 2019 AND 2020 29
FIGURE 8 VALUE CHAIN ANALYSIS: EUROPE CLINICAL TRIALS MARKET 30
FIGURE 9 PORTER'S FIVE FORCES ANALYSIS: EUROPE CLINICAL TRIALS MARKET 32
FIGURE 10 EUROPE CLINICAL TRIALS MARKET, PHASE SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION) 38
FIGURE 11 EUROPE CLINICAL TRIALS MARKET, BY PHASE, 2022 & 2030 (USD MILLION) 38
FIGURE 12 EUROPE CLINICAL TRIALS MARKET SHARE (%), BY PHASE, 2022 39
FIGURE 13 EUROPE CLINICAL TRIALS MARKET, STUDY DESIGN SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION) 43
FIGURE 14 EUROPE CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2022 & 2030 (USD MILLION) 44
FIGURE 15 EUROPE CLINICAL TRIALS MARKET SHARE (%), FOR STUDY DESIGN, 2022 45
FIGURE 16 EUROPE CLINICAL TRIALS MARKET, APPLICATION SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION) 47
FIGURE 17 EUROPE CLINICAL TRIALS MARKET, BY APPLICATION, 2022 & 2030 (USD MILLION) 48
FIGURE 18 EUROPE CLINICAL TRIALS MARKET SHARE (%), FOR APPLICATION, BY COUNTRY, 2022 49
FIGURE 19 EUROPE CLINICAL TRIALS MARKET, SERVICE TYPE SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION) 56
FIGURE 20 EUROPE CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2022 & 2030 (USD MILLION) 56
FIGURE 21 EUROPE CLINICAL TRIALS MARKET SHARE (%), FOR SERVICE TYPE, BY COUNTRY, 2022 57
FIGURE 22 EUROPE CLINICAL TRIALS MARKET, END USER SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION) 62
FIGURE 23 EUROPE CLINICAL TRIALS MARKET, FOR END USER, BY COUNTRY, 2022 & 2030 (USD MILLION) 63
FIGURE 24 EUROPE CLINICAL TRIALS MARKET SHARE (%), FOR END USER, BY COUNTRY, 2022 64
FIGURE 25 EUROPE MARKET ANALYSIS: CLINICAL TRIALS MARKET, 2019-2030 (USD MILLION) 69
FIGURE 26 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY, 2022 & 2030 (USD MILLION) 70
FIGURE 27 EUROPE: CLINICAL TRIALS MARKET SHARE (%), BY COUNTRY, 2022 71
FIGURE 28 BENCHMARKING OF MAJOR COMPETITORS 90
FIGURE 29 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE EUROPE CLINICAL TRIALS MARKET 91
FIGURE 30 EUROPE FILL FINISH MANUFACTURING MARKET: COMPETITIVE LANDSCAPE 92
FIGURE 31 SALES 2022 94
FIGURE 32 CHARLES RIVER LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT 97
FIGURE 33 CHARLES RIVER LABORATORIES: SWOT ANALYSIS 99
FIGURE 34 ICON PLC: FINANCIAL OVERVIEW SNAPSHOT 103
FIGURE 35 ICON PLC: SWOT ANALYSIS 105
FIGURE 36 LABORATORY CORPORATION OF AMERICA HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT 107
FIGURE 37 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS 108
FIGURE 38 PPD INC: SWOT ANALYSIS 111
FIGURE 39 SYNEOS HEALTH: FINANCIAL OVERVIEW SNAPSHOT 113
FIGURE 40 IQVIA: FINANCIAL OVERVIEW SNAPSHOT 118
FIGURE 41 IQVIA: SWOT ANALYSIS 119
FIGURE 42 MEDPACE INC: FINANCIAL OVERVIEW 121